Taken together, the in vivo results indicate that 131I-YZHER2: V2 exhibits promising efficacy and safety profiles, suggesting its potential as a TRNT agent for ovarian cancer with HER2 overexpression. Here, ERBB2 is linked to ovarian carcinoma.